secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0001127537-22-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M
-------------------------------------------------------------------------------

- Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).
- Q4 gross margin 74.8% (vs 72.0% YoY); FY gross margin 73.6% (vs 64.8%); improvement from production efficiencies.
- U.S. treatment centers for Zephyr Valves expanded to 214, a 45% increase since start of 2021.
- FY 2022 revenue guidance $55-60M; Q1 2022 revenue expected $9-10M due to COVID impact.
- Regulatory submission for Zephyr Valve approval in Japan made in December 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/0001127537-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/lung-20220223.htm
  HTML page:      https://secwatch.observer/filing/0001127537-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer